The stock of BioTelemetry, Inc. (NASDAQ:BEAT) is a huge mover today! About 270,723 shares traded hands. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 33.94% since April 4, 2016 and is uptrending. It has outperformed by 32.85% the S&P500.
The move comes after 5 months positive chart setup for the $433.35 million company. It was reported on Nov, 4 by Barchart.com. We have $32.27 PT which if reached, will make NASDAQ:BEAT worth $424.68 million more.
Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on November, 14. They expect $0.18 earnings per share, up 38.46% or $0.05 from last year’s $0.13 per share. BEAT’s profit will be $4.79M for 22.64 P/E if the $0.18 EPS becomes a reality. After $0.20 actual earnings per share reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts -10.00% negative EPS growth.
BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage
Out of 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioTelemetry has been the topic of 2 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock of BioTelemetry, Inc. (NASDAQ:BEAT) has “Buy” rating given on Tuesday, July 28 by Dougherty & Company. Sidoti initiated the shares of BEAT in a report on Tuesday, September 13 with “Buy” rating.
According to Zacks Investment Research, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania.”
Insitutional Activity: The institutional sentiment increased to 1.48 in 2016 Q2. Its up 0.50, from 0.98 in 2016Q1. The ratio increased, as 7 funds sold all BioTelemetry, Inc. shares owned while 43 reduced positions. 35 funds bought stakes while 39 increased positions. They now own 20.72 million shares or 1.56% less from 21.05 million shares in 2016Q1.
Moreover, Panagora Asset Mngmt has 0.02% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 250,503 shares. Citadel Advisors Lc reported 51,538 shares or 0% of all its holdings. The Wisconsin-based Cortina Asset Mngmt Ltd Liability has invested 0.45% in BioTelemetry, Inc. (NASDAQ:BEAT). Airain has 0.02% invested in the company for 25,762 shares. Kalmar Invs De holds 389,173 shares or 0.28% of its portfolio. Royal Bank Of Canada accumulated 18,660 shares or 0% of the stock. Voya Investment Management Ltd Liability reported 12,467 shares or 0% of all its holdings. State Street Corp accumulated 552,741 shares or 0% of the stock. Sawgrass Asset Management Limited holds 94,160 shares or 0.07% of its portfolio. Blackrock Institutional Trust Na reported 672,570 shares or 0% of all its holdings. Franklin Street Advsr Nc reported 14,500 shares or 0.04% of all its holdings. The California-based Globeflex Limited Partnership has invested 0.57% in BioTelemetry, Inc. (NASDAQ:BEAT). Art Advsr Ltd Liability Com holds 0.02% or 25,535 shares in its portfolio. Moreover, Millennium Mgmt Limited Liability Com has 0.01% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 346,542 shares. Community Fincl Bank Na holds 0.01% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 3,000 shares.
More notable recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Fool.com which released: “Here’s Why BioTelemetry, Inc. Is Soaring Today” on October 05, 2016, also Globenewswire.com with their article: “BioTelemetry, Inc. Reports Third Quarter 2016 Financial Results” published on November 02, 2016, Reuters.com published: “BRIEF-Biotelemetry Inc Q3 adj EPS $0.21 vs I/B/E/S view $0.18” on November 02, 2016. More interesting news about BioTelemetry, Inc. (NASDAQ:BEAT) were released by: Globenewswire.com and their article: “BioTelemetry, Inc. Reports First Quarter 2016 Financial Results” published on April 26, 2016 as well as Globenewswire.com‘s news article titled: “BioTelemetry, Inc. Announces the Completion of Its Acquisition of …” with publication date: May 11, 2016.
BEAT Company Profile
BioTelemetry, Inc. (BioTelemetry), incorporated on April 12, 2013, provides cardiac monitoring services, cardiac monitoring device manufacturing and cardiac laboratory services. The Firm operates through three divisions: Healthcare, Technology and Research. The Company’s subsidiary is CardioNet, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.